A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients
- Conditions
- HIV Infections
- Registration Number
- NCT00002168
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this study is to compare the safety and effectiveness of two anti-HIV drug combinations when given to HIV-infected patients who have never been treated with anti-HIV drugs. One drug combination is stavudine (d4T) plus didanosine (ddI) plus Crixivan. The other combination is Retrovir (AZT) plus Epivir (3TC) plus Crixivan.
- Detailed Description
100 patients will be randomized to receive Zerit (Stavudine) + Videx (Didanosine) + Crixivan (Indinavir) and 100 patients will be randomized to receive Retrovir (Zidovudine) + Epivir (Lamivudine) + Crixivan (Indinavir).
Patients will be treated for 48 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (13)
Univ of Nebraska
🇺🇸Omaha, Nebraska, United States
Anderson Clinical Research
🇺🇸Washington, District of Columbia, United States
Hosp Regional de Ponce - Area Vieja
🇵🇷Ponce, Puerto Rico
The Nalle Clinic / Clinical Research Dept
🇺🇸Charlotte, North Carolina, United States
George Washington Med Ctr / Clinical Trials Unit
🇺🇸Washington, District of Columbia, United States
East Bay AIDS Clinic
🇺🇸Berkeley, California, United States
Chicago Ctr for Clinical Research
🇺🇸Chicago, Illinois, United States
Univ of Pennsylvania / Infectious Diseases Division
🇺🇸Philadelphia, Pennsylvania, United States
Northwestern Univ
🇺🇸Chicago, Illinois, United States
Southwest Infectious Disease Association / PA
🇺🇸Dallas, Texas, United States
Univ of Texas Southwestern Med Ctr of Dallas
🇺🇸Dallas, Texas, United States
Harbor UCLA Med Ctr / Division of Immunology / N-24
🇺🇸Torrance, California, United States
Univ of North Carolina / Infectious Disease Division
🇺🇸Chapel Hill, North Carolina, United States